SN514-066b Enzyme in Deep Partial Thickness Burns
Enrolling by invitation · Phase 1/Phase 2
Conditions studied: Burn Injury
In brief
This study will examine the tolerability of a gel formulation of the enzyme SN514 in patients with burns suitable for enzymatic debridement. In a rising dose fashion by sequential cohort, concentrations of 0.1%, 0.2%, 0.4% and 0.8% will be tested. Groups of 3 will undergo daily debridement for up to 7 days. Extent of debridement and adverse signs and symptoms will be recorded daily. Dose escalation will stop if a dose level is found to be intolerable. Dose escalation may accelerate if a tested dose is entirely ineffective. There is no placebo control as all burn wounds require debridement.
Key facts
- Study ID
- NCT06628037
- Run by
- SERDA bv
- People needed
- 27
- Starts
- 2025-05-08
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-08-07
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USAISR Burn Center — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.